Education
About Us
Working with TipRanks
Follow Us
Revvity (RVTY)
NYSE:RVTY
Earnings Data
Report Date
Aug 04, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.14Last Year’s EPS
1.22Same Quarter Last Year
Moderate Buy
Based on 14 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 28, 2025
|% Change Since: -2.86%
|Next Earnings Date:Aug 04, 2025
Earnings Call Sentiment|Neutral
Revvity demonstrated resilience with strong organic growth and strategic innovations in diagnostics and software. However, the company faced challenges from academic customer spending and tariff pressures, which it is actively mitigating. The overall sentiment reflects a balanced view of the company's achievements and challenges.Company Guidance
In the Q1 2025 earnings call, Revvity provided guidance that reflects their resilience amid a challenging macroeconomic environment. The company achieved 4% organic growth, which aligned with expectations, despite unforeseen demand fluctuations from US academic customers affecting life science instruments. Adjusted EPS for the quarter exceeded expectations at $1.01, surpassing the projected $0.93 to $0.95 range. Revvity continued to demonstrate strong cash flow management with a 97% free cash flow conversion of adjusted net income and repurchased $154 million worth of shares. Looking ahead, the company reaffirmed its full-year adjusted EPS outlook of $4.90 to $5 and its organic growth outlook of 3% to 5%, with expectations of counterbalancing academic and instrumentation headwinds through robust performance in the Software division and reproductive health segment. Despite a $135 million gross tariff impact potential, Revvity expects to mitigate most of it by the end of June, with only a 60 basis point negative impact on adjusted operating margins.Solid Organic Growth
Revvity achieved 4% organic growth in Q1 2025, in line with expectations, driven by diagnostics and software segments.
Strong Diagnostics Performance
The Diagnostics segment grew 5% organically, supported by the resilient newborn screening and immunodiagnostics businesses.
Signals Software Business Success
Signals Software grew over 20% organically in Q1, with expectations for even stronger growth in Q2, positioning it for another year of strong double-digit growth.
Share Buyback Program
Revvity repurchased $154 million of its shares in Q1, resulting in a 6% decline in total shares outstanding since mid-2023.
Innovations and New Collaborations
Revvity expanded its alliance with Genomics England for newborn genomic sequencing and secured FDA approval for an automated TB testing platform.
Robust Cash Flow Management
The company delivered 97% free cash flow conversion of adjusted net income in Q1.
---
RVTY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RVTY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 28, 2025 | $94.29 | $95.06 | +0.82% |
| Jan 31, 2025 | $126.74 | $126.04 | -0.55% |
| Nov 04, 2024 | $120.88 | $124.65 | +3.12% |
| Jul 29, 2024 | $114.93 | $125.35 | +9.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Revvity (RVTY) report earnings?
Revvity (RVTY) is schdueled to report earning on Aug 04, 2025, TBA Not Confirmed.
What is Revvity (RVTY) earnings time?
Revvity (RVTY) earnings time is at Aug 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RVTY EPS forecast?
RVTY EPS forecast for the fiscal quarter 2025 (Q2) is 1.14.
---
